Abstracts
3427241
(#47) Inpatient Length of Stay and Healthcare Professional Preferences for Initiating TV-46000, a Long-Acting Subcutaneous Antipsychotic, or Intramuscular Paliperidone Palmitate in Patients Hospitalized With Schizophrenia
Abstract: Background: Long-acting injectable antipsychotics (LAIs) improve adherence and reduce relapse in schizophrenia, but product-specific initiation requirements may influence hospitalization and healthcare resource utilization. TV-46000, a subcutaneous risperidone formulation, requires no loading dose, whereas paliperidone palmitate once-monthly (PP1m) requires two initiation doses. This study compared hospitalization-related outcomes and healthcare professional (HCP) perspectives for inpatient initiation of TV-46000 versus PP1m.
Methods: This United States-based, retrospective, observational cohort study included electronic health record chart reviews and an online survey of HCPs. HCPs contributed matched patient charts for adults with schizophrenia newly initiated on TV-46000 or PP1m during hospitalization. The primary outcome was length of stay (LOS) from LAI initiation to discharge. Secondary outcomes included 30-, 60-, and 90-day schizophrenia-related rehospitalization after discharge, timing of the second PP1m initiation dose, and HCP attitudes toward dosing and ease-of-use features.
Results: The analysis included 137 TV-46000-treated and 94 PP1m-treated patients who received both initiation doses during hospitalization. LOS from initiation to discharge was shorter with TV-46000 than PP1m (mean ± SD: 12.6 ± 10.0 vs 15.5 ± 10.2 days; P = .033; median: 9 vs 12 days). Rehospitalization rates did not differ at 30, 60, or 90 days after discharge. Of 58 HCPs surveyed, more preferred TV-46000 overall, whereas PP1m was favored for onset of action. Thirty-one percent reported the two-dose initiation requirement for PP1m influenced decisions to extend hospitalization.
Conclusions: Initiation of TV-46000 during hospitalization was associated with statistically significantly shorter LOS than PP1m. HCP perspectives further underscore practical considerations for LAI selection.
Short Description: This study compared outcomes in patients hospitalized with schizophrenia and healthcare professional (HCP) preferences for 2 long-acting injectable antipsychotics with different initiation requirements: TV-46000 (1 dose) and intramuscular paliperidone palmitate (PP1m; 2 doses separated by 4-7 days). TV-46000 was associated with shorter hospital stays and higher HCP satisfaction regarding ease of use and dosing.
Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC
Methods: This United States-based, retrospective, observational cohort study included electronic health record chart reviews and an online survey of HCPs. HCPs contributed matched patient charts for adults with schizophrenia newly initiated on TV-46000 or PP1m during hospitalization. The primary outcome was length of stay (LOS) from LAI initiation to discharge. Secondary outcomes included 30-, 60-, and 90-day schizophrenia-related rehospitalization after discharge, timing of the second PP1m initiation dose, and HCP attitudes toward dosing and ease-of-use features.
Results: The analysis included 137 TV-46000-treated and 94 PP1m-treated patients who received both initiation doses during hospitalization. LOS from initiation to discharge was shorter with TV-46000 than PP1m (mean ± SD: 12.6 ± 10.0 vs 15.5 ± 10.2 days; P = .033; median: 9 vs 12 days). Rehospitalization rates did not differ at 30, 60, or 90 days after discharge. Of 58 HCPs surveyed, more preferred TV-46000 overall, whereas PP1m was favored for onset of action. Thirty-one percent reported the two-dose initiation requirement for PP1m influenced decisions to extend hospitalization.
Conclusions: Initiation of TV-46000 during hospitalization was associated with statistically significantly shorter LOS than PP1m. HCP perspectives further underscore practical considerations for LAI selection.
Short Description: This study compared outcomes in patients hospitalized with schizophrenia and healthcare professional (HCP) preferences for 2 long-acting injectable antipsychotics with different initiation requirements: TV-46000 (1 dose) and intramuscular paliperidone palmitate (PP1m; 2 doses separated by 4-7 days). TV-46000 was associated with shorter hospital stays and higher HCP satisfaction regarding ease of use and dosing.
Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products R&D LLC
